Literature DB >> 23481310

Hepatitis B and C co-infection in HIV/AIDS population in the state of Michigan.

Z A Butt1, M J Wilkins, E Hamilton, D Todem, J C Gardiner, M Saeed.   

Abstract

A retrospective cohort study was conducted from 1 January 2006 to 31 December 2009 in Michigan to estimate the prevalence of HIV and hepatitis co-infection and identify associated factors. The prevalence of co-infection was 4.1% [95% confidence interval (CI) 3.8-4.5]. Multivariable logistic regression analysis revealed a significant association between co-infection and being male and: of Black race [odds ratio (OR) 2.0, 95% CI 1.2-3.6] and of Other race (OR 3.5, 95% CI 1.7-7.0) compared to Hispanic race. A significant association was found between co-infection and risk categories of blood products (OR 11.1, 95% CI 6.2-20.2), injecting drug user (IDU) (OR 3.6, 95% CI 2.7-4.8) and men who have sex with men/IDU (OR 3.4, 95% CI 2.4-4.9) in addition to two interactions; one between sex and current HIV status and the other between current HIV status and age at HIV diagnosis. Our results document the changing epidemiology of HIV-hepatitis co-infection which can guide preventive measures and interventions to reduce the prevalence of hepatitis co-infection.

Entities:  

Mesh:

Year:  2013        PMID: 23481310      PMCID: PMC9151374          DOI: 10.1017/S0950268813000538

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  19 in total

1.  Gender differences in HIV risk behaviors among young injectors and their social network members.

Authors:  Susanne B Montgomery; Justeen Hyde; Christine Johnson De Rosa; Louise Ann Rohrbach; Susan Ennett; S Marie Harvey; Michael Clatts; Ellen Iverson; Michele D Kipke
Journal:  Am J Drug Alcohol Abuse       Date:  2002       Impact factor: 3.829

Review 2.  Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century.

Authors:  D M Dwyre; L P Fernando; P V Holland
Journal:  Vox Sang       Date:  2011-01       Impact factor: 2.144

3.  Seroprevalence of HBV, HCV and HIV co-infection in selected individuals from state of São Paulo, Brazil.

Authors:  Alexandre Martins Portelinha Filho; Charles Ulloffo do Nascimento; Talita Nicastro Tannouri; Charlene Troiani; Eloah Lopes Ascêncio; Renata Bonfim; Lourdes Aparecida Zampieri D'Andrea; Luiz Euribel Prestes-Carneiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-11       Impact factor: 2.743

4.  Epidemiology of HIV/HCV coinfection in patients cared for at the Tropical Medicine Foundation of Amazonas.

Authors:  Marilú Barbieri Victoria; Flamir da Silva Victoria; Kátia Luz Torres; Simone Kashima; Dimas Tadeu Covas; Adriana Malheiro
Journal:  Braz J Infect Dis       Date:  2010 Mar-Apr       Impact factor: 1.949

5.  Hepatitis C is more severe in drug users with human immunodeficiency virus infection.

Authors:  R Romeo; M G Rumi; M F Donato; M A Cargnel; P Viganò; M Mondelli; B Cesana; M Colombo
Journal:  J Viral Hepat       Date:  2000-07       Impact factor: 3.728

6.  The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.

Authors:  Maria Dorrucci; Catia Valdarchi; Barbara Suligoi; Mauro Zaccarelli; Alessandro Sinicco; Massimo Giuliani; David Vlahov; Patrizio Pezzotti; Giovanni Rezza
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

7.  HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.

Authors:  D Lincoln; K Petoumenos; G J Dore
Journal:  HIV Med       Date:  2003-07       Impact factor: 3.180

8.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects.

Authors:  Scott E Kellerman; Debra L Hanson; A D McNaghten; Patricia L Fleming
Journal:  J Infect Dis       Date:  2003-08-05       Impact factor: 5.226

9.  Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Authors:  Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.

Authors:  Katie B Anderson; Jodie L Guest; David Rimland
Journal:  Clin Infect Dis       Date:  2004-10-25       Impact factor: 9.079

View more
  4 in total

1.  HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities.

Authors:  K A Bosh; J R Coyle; V Hansen; E M Kim; S Speers; M Comer; L M Maddox; S Khuwaja; W Zhou; A Jatta; R Mayer; A D Brantley; N W Muriithi; R Bhattacharjee; C Flynn; L Bouton; B John; J Keusch; C A Barber; K Sweet; C Ramaswamy; E F Westheimer; L VanderBusch; A Nishimura; A Vu; L Hoffman-Arriaga; E Rowlinson; A O Carter; L E Yerkes; W Li; J R Reuer; L J Stockman; T Tang; J T Brooks; E H Teshale; H I Hall
Journal:  Epidemiol Infect       Date:  2018-04-11       Impact factor: 2.451

2.  Survival of HIV-positive individuals with hepatitis B and C infection in Michigan.

Authors:  Z A Butt; M J Wilkins; E Hamilton; D Todem; J C Gardiner; M Saeed
Journal:  Epidemiol Infect       Date:  2013-11-29       Impact factor: 4.434

3.  Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis.

Authors:  Lucy Platt; Clare E French; Catherine R McGowan; Keith Sabin; Erin Gower; Adam Trickey; Bethan McDonald; Jason Ong; Jack Stone; Philippa Easterbrook; Peter Vickerman
Journal:  J Viral Hepat       Date:  2019-12-22       Impact factor: 3.728

4.  HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics.

Authors:  C Prussing; C Chan; J Pinchoff; L Kersanske; K Bornschlegel; S Balter; A Drobnik; J Fuld
Journal:  Epidemiol Infect       Date:  2014-08-29       Impact factor: 4.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.